<DOC>
	<DOCNO>NCT00513669</DOCNO>
	<brief_summary>This phase Ib double-blind randomize placebo control age-deescalating trial ass sagety immunogenicity two virosome formulate anti-malaria vaccine component ( PEV 301 PEV 302 ) administer combination healthy semi-immune Tanzanian adult child .</brief_summary>
	<brief_title>Phase Ib Trial Two Virosome Formulated Malaria Vaccine Components ( PEV 301 , PEV 302 ) Tanzania</brief_title>
	<detailed_description>Volunteers screen , enrol , injected vaccine comparator follow clinician Bagamoyo Research Training Unit Ifakara Health Research Development Center ( BRTU-IHRDC ) . First , 10 adult male enrol randomized 2 group : Group AV ( n=8 ) inject vaccine combination group AP ( n=2 ) vaccinate placebo=comparator ( Inflexal V ) . 5 week later , 8 child enrol first randomize 2 group : Group CV ( n=6 ) inject vaccine combination group CP ( n=2 ) vaccinate comparator . 1 week later , rest cohort ( n=32 ) enrol randomized 2 group : Group CV ( n=26 ) inject vaccine combination group CP ( n=6 ) vaccinate comparator . Immunogenicity assessments humoral immune response make baseline ( day -10 -2 ) , day 30 ( +4 ) , day 90 ( +4 ) ( day 2nd vaccination ) , 120 ( +4 ) , 180 ( +7 ) , 365 ( +14 ) . Cellular immune response assess 1st vaccination ( day 0 ) , two week 2nd vaccination ( day 104 ±2 ) , one year 1st vaccination ( day 365 ) Safety assessment make investigator baseline ( day -10 -2 , 1st immunization ) day 1 , 2 , 3 , 7 , 14 , 30 vaccination .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Male volunteer age 18 45 year adult group , child sex age 59 year schoolchildren group 2 . Written inform consent obtain volunteer ( adult ) guardian/ legal representative ( child ) . In case patient illiterate , impartial witness present entire consent procedure 3 . Free obvious health problem establish medical history clinical examination enter study 4 . Body Mass Index 18 30 adult ; MUAC le 12 child 1 . Use investigational nonregistered drug vaccine within 30 day precede first dose study vaccine , plan use study period safety followup 2 . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior first vaccine dose 3 . Any chronic drug therapy continue study period 4 . Any confirmed suspect acquire immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection , history congenital hereditary immunodeficiency 5 . History allergic disease reaction likely exacerbate component vaccine 6 . Acute disease time enrollment . Acute disease define presence moderate severe illness without fever ( defined temperature 37.5°C ) 7 . Acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory screen test 8 . Acute chronic diabetes 9 . History chronic alcohol consumption and/or intravenous drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Malaria</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Falciparum</keyword>
	<keyword>Trial</keyword>
	<keyword>Phase I</keyword>
	<keyword>Safety</keyword>
	<keyword>Immunogenicity</keyword>
</DOC>